About OraSure Technologies, Inc. - Common Stock (OSUR)
Orasure Technologies, Inc. is a medical device company that specializes in the development, manufacturing, and distribution of proprietary devices for the sampling and testing of human biological fluids. The company is particularly known for its innovative oral fluid collection technologies, which enable non-invasive testing for various health conditions, including infectious diseases, drug detection, and genetic testing. Orasure's products are designed to enhance patient comfort and convenience, streamline healthcare processes, and improve access to important diagnostic information, thereby contributing to public health initiatives and expanding testing capabilities in various medical fields. Read More
BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025.
Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective
Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters reported.
BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025.
BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025.
IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Targeted Genomics LLC, developer of GlutenID, the first and only U.S. Food and Drug Administration (FDA) cleared direct-to-consumer (DTC) test for celiac disease genetics, today announced a commercial collaboration with OraSure Technologies, Inc. (NASDAQ: OSUR) manufacturer of ORAcollect®·Dx, the only FDA cleared saliva collection device for general over-the-counter (OTC) use. The collaboration expands consumer access to at-home celiac genetic testing.
BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025.
BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025.
BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on hand.
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2024.
BETHLEHEM, Pa., Feb. 14, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2024 financial results and certain business developments for 5 p.m. ET on February 25, 2025.
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. OraSure’s presentation is scheduled for Thursday, January 16, 2025 at 9:00 a.m. PT.
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, January 7th by OraSure Technologies, Inc. (NASDAQ: OSUR), please note that the first sentence of the release (read "OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents.") is incomplete. The corrected release follows:
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.
